Literature DB >> 9625815

Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089.

H Huynh1, M Pollak, J C Zhang.   

Abstract

Prostate cancer and benign prostate hyperplasia (BPH) are major public health problems. Prostate epithelial cell proliferation is regulated by insulin-like growth factor I (IGF-I) which is mitogenic and anti-apoptotic, and IGF binding protein 3 (IGFBP-3) which is an apoptotic agent in these cells. We demonstrate that the 1,25(OH)2D3 and its analog EB1089-induced growth inhibition was associated with increased IGFBP-3 mRNA abundance, IGFBP-3 mRNA stability, IGFBP-3 protein accumulation, and decreased IGF-II gene expression. Anti-IGF-II antibody and exogenous recombinant human IGFBP-3 inhibit PC-3 cell proliferation. The results document the inhibitory effects of 1,25(OH)2D3 and EB1089 on the IGF system of mitogens in prostate cancer cells, and suggest a potential therapeutic use of EB1089 in treatment of BPH and prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625815     DOI: 10.3892/ijo.13.1.137

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

Review 1.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

2.  Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.

Authors:  Kimmie Ng; Daniel J Sargent; Richard M Goldberg; Jeffrey A Meyerhardt; Erin M Green; Henry C Pitot; Bruce W Hollis; Michael N Pollak; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

Review 3.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

Review 4.  Vitamin D and cancer: the promise not yet fulfilled.

Authors:  Daniel D Bikle
Journal:  Endocrine       Date:  2014-01-09       Impact factor: 3.633

Review 5.  Extraskeletal actions of vitamin D.

Authors:  Daniel D Bikle
Journal:  Ann N Y Acad Sci       Date:  2016-07       Impact factor: 5.691

6.  1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest.

Authors:  Michele N Washington; Jung-Sun Kim; Nancy L Weigel
Journal:  Prostate       Date:  2011-01-01       Impact factor: 4.104

Review 7.  Potent 19-norvitamin D analogs for prostate and liver cancer therapy.

Authors:  Atsushi Kittaka; Akihiro Yoshida; Kun-Chun Chiang; Masashi Takano; Daisuke Sawada; Toshiyuki Sakaki; Tai C Chen
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

Review 8.  Antiproliferative role of vitamin D and its analogs--a brief overview.

Authors:  Pratik Banerjee; Malay Chatterjee
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

Review 9.  Molecular actions of vitamin D contributing to cancer prevention.

Authors:  James C Fleet
Journal:  Mol Aspects Med       Date:  2008-08-08

10.  Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells.

Authors:  P Kanagaraj; M R Vijayababu; B Ravisankar; J Anbalagan; M M Aruldhas; J Arunakaran
Journal:  J Cancer Res Clin Oncol       Date:  2007-01-12       Impact factor: 4.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.